MedTrace Logo

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

NCT06265727 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 348

Last updated 2026-01-08

No results posted yet for this study

Summary

The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4.

The main questions it aims to answer are:

What is the the safe and effective dose of CRB-701? What cancers can be treated effectively with CRB-701?

Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701. They will have blood tests, CT or MRI Scans, and other assessments to measure whether CRB-701 has an effect on tumors.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

CRB-701

Nectin-4 targeted Antibody Drug Conjugate (ADC)

DRUG

Anti-PD-1

checkpoint inhibitor

Sponsors & Collaborators

  • CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

    collaborator INDUSTRY

  • Corbus Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • David Pinato, MD · Imperial College London

  • Ian Hodgson, PhD · Corbus International Ltd

  • Ari Rosenberg, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2027-01-16
Completion
2027-01-27
FDA Drug
Yes

Countries

  • United States
  • France
  • Italy
  • Moldova
  • Romania
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06265727 on ClinicalTrials.gov